Skip to content

Study · Non-randomized trial · n = 25 · 2013

4 results

Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

Fang J, Landersdorfer CB, Cirincione B, Jusko WJ

The AAPS journal2 Oct 2012Cited by 12 (Europe PMC)

PMID23054970 (opens in a new tab)PMCIDPMC3535104 (opens in a new tab)DOI10.1208/s12248-012-9409-7 (opens in a new tab)PepBankPUB-23054970
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In subjects with type 1 diabetes, pramlintide lowered overall postprandial plasma glucose AUC versus placebo.

    In plain wordsIn type 1 diabetes, pramlintide lowered total post-meal blood glucose exposure versus placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial plasma glucose AUC
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous · bolus and 2-h intravenous infusionsAs given in this study (human).

    Source sentences

    Summary
    Pramlintide lowered overall postprandial plasma glucose AUC (AUC(net)) and delayed the time to peak plasma glucose after a meal (T (max)).
    2 context sentences
    Summary · context
    Plasma glucose and drug concentrations were obtained following bolus and 2-h intravenous infusions of pramlintide at three dose levels or placebo in 25 T1DM subjects during the postprandial period in a crossover study.
    Summary · context
    The original clinical data were reanalyzed by mechanism-based population modeling.
  2. 02HumanNon-randomized trialEfficacy outcome

    In subjects with type 1 diabetes, pramlintide delayed peak postprandial plasma glucose versus placebo, independently of dose within the studied range.

    In plain wordsIn type 1 diabetes, pramlintide delayed peak post-meal glucose versus placebo, independently of dose within the studied range.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseTime to peak postprandial glucose
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous · bolus and 2-h intravenous infusionsAs given in this study (human).

    Source sentences

    Summary
    The observed increase in glucose T (max) following pramlintide treatment was independent of dose within the studied dose range and was adequately described by a dose-independent, maximum pramlintide effect on gastric emptying of glucose in the model.
    3 context sentences
    Summary · context
    Pramlintide lowered overall postprandial plasma glucose AUC (AUC(net)) and delayed the time to peak plasma glucose after a meal (T (max)).
    Summary · context
    Plasma glucose and drug concentrations were obtained following bolus and 2-h intravenous infusions of pramlintide at three dose levels or placebo in 25 T1DM subjects during the postprandial period in a crossover study.
    Summary · context
    The original clinical data were reanalyzed by mechanism-based population modeling.

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 03HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialPharmacokinetics

    In population modelling, pramlintide pharmacokinetics followed a two-compartment model with zero-order infusion and first-order elimination.

    In plain wordsComputer modelling described pramlintide movement with two compartments, constant infusion, and first-order elimination.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicablePharmacokinetic model structure
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Pramlintide pharmacokinetics followed a two-compartment model with zero-order infusion and first-order elimination.
    2 context sentences
    Summary · context
    Plasma glucose and drug concentrations were obtained following bolus and 2-h intravenous infusions of pramlintide at three dose levels or placebo in 25 T1DM subjects during the postprandial period in a crossover study.
    Summary · context
    The original clinical data were reanalyzed by mechanism-based population modeling.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 04HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialMechanism

    In population modelling, pramlintide inhibition of endogenous glucose production had estimated capacity 0.995 and sensitivity 23.8 pmol/L.

    In plain wordsComputer modelling estimated pramlintide glucose-production inhibition capacity at 0.995 and sensitivity at 23.8 pmol/L.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableEndogenous glucose production inhibition parameters
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    I (max)
    0.995 dimensionless
    model estimate
    IC(50)
    23.8 pmol/L
    model estimate

    Source sentences

    Summary
    The inhibition of endogenous glucose production by pramlintide was described using a sigmoidal function with capacity and sensitivity parameter estimates of 0.995 for I (max) and 23.8 pmol/L for IC(50).
    2 context sentences
    Summary · context
    Plasma glucose and drug concentrations were obtained following bolus and 2-h intravenous infusions of pramlintide at three dose levels or placebo in 25 T1DM subjects during the postprandial period in a crossover study.
    Summary · context
    The original clinical data were reanalyzed by mechanism-based population modeling.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.